iBio (IBIO) Corporate presentation summary

Industry landscape and unmet needs

• Incretin class agonists, such as GLP-1 drugs, have transformed obesity treatment, with over 10% of American adults having used them, but challenges remain in durability, lean mass preservation, and tolerability.

• Weight loss with GLP-1s often results in loss of lean tissue, increasing frailty fracture risk and highlighting the need for therapies that preserve muscle mass.

• There is a shift toward therapies that improve the quality of weight loss, reduce side effects, and sustain results beyond current GLP-1 options.

Pipeline and portfolio strategy

• The portfolio targets multiple mechanisms to address gaps left by GLP-1 therapies, focusing on fat-specific weight reduction, muscle mass preservation, and reduced dosing frequency.

• Lead programs include IBIO-610 (Activin E antibody), Myostatin x Activin A bispecific antibody, and IBIO-600 (long-acting myostatin antibody), with several early-stage and partnered programs.

• Anticipated milestones include IND-equivalent filings and Phase 1 initiations for IBIO-610 and IBIO-600 between 1H 2026 and 1H 2027, subject to funding.

IBIO-610: Activin E antibody

• Targets Activin E, a hepatokine linked to adiposity and cardiometabolic risk; genetic loss of function is associated with reduced obesity and diabetes risk.

• Preclinical studies show fat-specific weight loss without lean mass loss, synergistic effects with GLP-1 agonists, and prevention of weight regain after GLP-1 discontinuation.

• Demonstrates high-affinity binding, potent pathway inhibition, and manufacturability for scalable production.

• Non-human primate studies indicate selective fat reduction, lean mass preservation, and extended half-life, supporting infrequent dosing in humans.